#United States #Princeton #pharmaceuticals #Kenox Pharmaceuticals #OINDPs

Kenox Pharmaceuticals Enhances Drug Development Services

Kenox Pharmaceuticals Inc., a swiftly advancing company in the pharmaceutical industry, has announced an exciting expansion of its capabilities related to the development of Orally Inhaled and Nasal Drug Products (OINDPs). From its base in Princeton, New Jersey, Kenox is making significant strides by introducing small scale non-sterile GMP capabilities to its arsenal. This development is aimed at supporting Good Laboratory Practice (GLP) pre-clinical studies, which is a crucial step in the drug development process.

The addition of these capabilities underlines Kenox's unwavering commitment to fostering innovation and streamlining the journey from initial molecular development to clinical application. With this recent enhancement, Kenox seeks to provide its partners and clients with valuable resources and expert knowledge, thus accelerating the availability of life-changing therapies in the market.

New Capabilities to Support Drug Development

The newly incorporated features at Kenox include a state-of-the-art clean room designed for compounding, fill-finish processes, and the release of non-sterile nasal sprays and dry powders. In anticipation of future demands, Kenox is also exploring further enhancements to facilitate small scale GMP batch manufacturing for clinical trials, specifically targeting Phase I and II developments for both non-sterile and sterile formulations.

This innovative approach aims to make the early phases of drug development more efficient and less risky for clients. By offering a streamlined solution from molecule creation to clinical trial initiation, Kenox has positioned itself as a one-stop-shop for any pharmaceutical innovator.

Sitaram Velaga, the Founder, President, and CEO of Kenox Pharmaceuticals, expressed his enthusiasm regarding this development, stating how the timely execution of this expansion could not have been achieved without the cohesive effort of the dedicated team. He acknowledged the foundational support received from partners, clients, various vendors, and facilities management. Velaga emphasized that this advancement is not just about increasing capabilities, but also about reinforcing their commitment to assist partners in developing cutting-edge therapeutics addressing unmet medical needs. Their focus remains steadfast on quality assurance, efficiency, project goal adherence, and strict timelines.

Versatility Across Therapeutic Areas

With these enhancements, Kenox Pharmaceuticals is now equipped to support a broad spectrum of OINDP dosage forms aimed at diverse therapeutic areas. These include, but are not limited to, cardiology, psychiatry, pain management, antimicrobial and antiviral therapies, as well as rare diseases. This multifaceted approach underscores Kenox's thorough understanding of formulation design, pre-clinical and clinical manufacturing practices, and the regulatory landscape.

Moreover, their unique flexibility and scalability allow Kenox to cater to a wide range of clients, from budding start-ups to established pharmaceutical giants. This adaptability has proven essential in the fast-evolving pharmaceutical landscape, where the need for rapid and efficient development capabilities is great.

About Kenox Pharmaceuticals

Founded in 2018, Kenox Pharmaceuticals specializes in the development of pharmaceutical aerosol products. Their product range encompasses soft mist inhalers, pressurized metered dose inhalers, dry powder inhalers, nebulizers, nasal sprays, and ophthalmic products. Acting as a contract development organization, Kenox provides extensive expertise in formulation design, manufacturing, and testing in accordance with established compendial standards.

As the healthcare landscape evolves, Kenox remains committed to supporting the development of innovative therapeutic solutions, ultimately working towards enhancing patient care and improving health outcomes for communities worldwide.

For more details, please contact Kenox through their media inquiries at [email protected] or for marketing and business development outreach at [email protected]